Base de dados : MEDLINE
Pesquisa : D02.455.849.919.530.466 [Categoria DeCS]
Referências encontradas : 1395 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 140 ir para página                         

  1 / 1395 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29363925
[Au] Autor:Bykov MI; Basov AA; Esaulenko EE; Kurzanov AN
[Ti] Título:[Experimental study of influence of lipophilic products of phytogenic origin on lipid metabolism in rats].
[So] Source:Vopr Pitan;84(5):31-8, 2015.
[Is] ISSN:0042-8833
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The article presents the results of biochemical evaluation of metabolic effects of lipophilic products of plant origin among which such oils as linseed, black nuts and walnuts oils as well as medicine «Phosphogliv¼ were selected as the most promising ones. The influence of the studied substances on lipid metabolism in experiment on male rats (170­220 g body weight) with modeled acute hepatotoxicity with carbon tetrachloride (that was achieved by subcutaneous injection of 50% oil solution of carbon tetrachloride ­ 0.5 ml/100 g of the body mass once a day during 3 days) has been investigated. Liver function was assessed by triacylglycerols content in the serum, total, esterified and nonesterified cholesterol, cholesterol in the lipoproteins of high, low and very low density, as well as by the nonesterified cholesterol and phospholipids content in the hemolysate of red blood cells. Carbon tetrachloride hepatotoxic damage was accompanied by the development of severe hypercholesterolemia associated both with the increase in total cholesterol and its content in low density lipoproteins alongside the reducing of the cholesterol concentration in high density lipoproteins, resulted in secondary dyslipoproteinemia. Inhibition of the esterification of cholesterol processes as well as the decrease in the triacylglycerols concentration was observed. It is connected with the triacylglycerols endogenous synthesis blocking in the liver, resulted from its toxic damage. It is also confirmed by cholesterol content reducing in the lipoproteins of very low density. In erythrocytes of rats with CCl4 intoxication phospholipid content decreased while the amount of nonesterified cholesterol that is a component of cell membranes, influencing the proteins and lipids diffusion, which reduces the mobility of the fatty acid residues of phospholipids, increased. The injection of the black nuts and walnuts oils as well as flax oil (intragastric injections 0.2 ml daily in the morning before the main feeding from the 7th to the 30th day of the experiment, n=25 in each group) to rats with liver failure induced by carbon tetrachloride, contributed to the partial restoration of liver tissue structure and statistically reliable decrease of lipid metabolism. Decrease in the total cholesterol content by 17.5% in the group of animals treated with linseed oil was observed; LDL cholesterol also decreased under the influence of walnuts and black nuts oils by 36.7 and 40.6% respectively. The increase in the content of phospholipids in erythrocytes of rats when administered by the studied lipophilic products has made it possible to prove the improvement of the cell membranes rheological properties. The results of the study of the influence of linseed, black nuts and walnuts oils as well as medicine «Phosphogliv¼ on animals with hepatotoxicity by CCl4 have proved positive effect of these lipophilic substances on lipid metabolism.
[Mh] Termos MeSH primário: Ração Animal
Ácido Glicirrízico/farmacologia
Óleo de Semente do Linho/farmacologia
Metabolismo dos Lipídeos/efeitos dos fármacos
Fígado/metabolismo
Fosfatidilcolinas/farmacologia
[Mh] Termos MeSH secundário: Animais
Intoxicação por Tetracloreto de Carbono/metabolismo
Intoxicação por Tetracloreto de Carbono/patologia
Combinação de Medicamentos
Fígado/patologia
Masculino
Ratos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Phosphatidylcholines); 0 (Phosphogliv); 6FO62043WK (Glycyrrhizic Acid); 8001-26-1 (Linseed Oil)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180125
[St] Status:MEDLINE


  2 / 1395 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28731703
[Au] Autor:Selyutina OY; Apanasenko IE; Khalikov SS; Polyakov NE
[Ad] Endereço:Voevodsky Institute of Chemical Kinetics and Combustion of Siberian Branch of the Russian Academy of Sciences , Institutskaya Street, 3, 630090, Novosibirsk, Russia.
[Ti] Título:Natural Poly- and Oligosaccharides as Novel Delivery Systems for Plant Protection Compounds.
[So] Source:J Agric Food Chem;65(31):6582-6587, 2017 Aug 09.
[Is] ISSN:1520-5118
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To increase the bioavailability of plant protection products, we have applied a new approach based on noncovalent association with natural water-soluble polysaccharides and oligosaccharides as delivery systems (DSs). The mechanochemical technique has been applied to prepare the solid-state nanodispersed compositions of antidote 1,8-naphthalic anhydride (NA) with arabinogalactan, sodium salt of carboxymethylcellulose, and glycyrrhizin as DSs. The effect of DSs on the solubility and the penetration of NA into the seeds of barley and wheat has been investigated by various physicochemical techniques. All DSs considerably enhance the solubility of NA and improve its penetration into the grain. The influence of polysaccharides and oligosaccharides on artificial lipid membranes was studied by the NMR relaxation method. It was concluded that the effect of polysaccharides and oligosaccharides on the penetration efficacy of plant protection products might be associated with the detected solubility enhancement and the affinity of DSs to the surface of cell membranes.
[Mh] Termos MeSH primário: Portadores de Fármacos/química
Sistemas de Liberação de Medicamentos/instrumentação
Oligossacarídeos/química
Doenças das Plantas/prevenção & controle
Polissacarídeos/química
[Mh] Termos MeSH secundário: Sistemas de Liberação de Medicamentos/métodos
Ácido Glicirrízico/química
Naftalenos/química
Praguicidas/química
Praguicidas/farmacologia
Sementes/efeitos dos fármacos
Sementes/crescimento & desenvolvimento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Carriers); 0 (Naphthalenes); 0 (Oligosaccharides); 0 (Pesticides); 0 (Polysaccharides); 32RS852X55 (1,8-naphthalenedicarboxylic acid anhydride); 6FO62043WK (Glycyrrhizic Acid)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170818
[Lr] Data última revisão:
170818
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170722
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jafc.7b02591


  3 / 1395 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28724837
[Au] Autor:Uchiyama N; Kamakura H; Masada S; Tsujimoto T; Hosoe J; Tokumoto H; Maruyama T; Goda Y; Hakamatsuka T
[Ad] Endereço:National Institute of Health Sciences (NIHS).
[Ti] Título:Chemical Analysis of Counterfeit Hepatitis C Drug Found in Japan.
[So] Source:Yakugaku Zasshi;137(10):1265-1276, 2017 10 01.
[Is] ISSN:1347-5231
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:In January 2017, counterfeits of the hepatitis C drug 'HARVONI Combination Tablets' (HARVONI ) were found at a pharmacy chain through unlicensed suppliers in Japan. A total of five lots of counterfeit HARVONI (samples 1-5) bottles were found, and the ingredients of the bottles were all in tablet form. Among them, two differently shaped tablets were present in two of the bottles (categorized as samples 2A, 2B, 4A, and 4B). We analyzed the total of seven samples by high-resolution LC-MS, GC-MS and NMR. In samples 2A, 3 and 4B, sofosbuvir, the active component of another hepatitis C drug, SOVALDI Tablets 400 mg (SOVALDI ), was detected. In sample 4A, sofosbuvir and ledipasvir, the active components of HARVONI , were found. A direct comparison of the four samples and genuine products showed that three samples (2A, 3, 4B) are apparently SOVALDI and that sample 2A is HARVONI . In samples 1 and 5, several vitamins but none of the active compounds usually found in HARVONI (i.e., sofosbuvir and ledipasvir) were detected. Our additional investigation indicates that these two samples are likely to be a commercial vitamin supplement distributed in Japan. Sample 2B, looked entirely different from HARVONI and contained several herbal constitutents (such as ephedrine and glycyrrhizin) that are used in Japanese Kampo formulations. A further analysis indicated that sample 2B is likely to be a Kampo extract tablet of Shoseiryuto which is distributed in Japan. Considering this case, it is important to be vigilant to prevent a recurrence of distribution of counterfeit drugs.
[Mh] Termos MeSH primário: Antivirais/química
Benzimidazóis/química
Medicamentos Falsificados/química
Fluorenos/química
Hepatite C/tratamento farmacológico
Uridina Monofosfato/análogos & derivados
[Mh] Termos MeSH secundário: Benzimidazóis/análise
Cromatografia Líquida
Medicamentos de Ervas Chinesas/análise
Efedrina/análise
Fluorenos/análise
Cromatografia Gasosa-Espectrometria de Massas
Ácido Glicirrízico/análise
Japão
Espectroscopia de Ressonância Magnética
Espectrometria de Massas
Sofosbuvir/análise
Comprimidos
Uridina Monofosfato/química
Vitaminas/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (Benzimidazoles); 0 (Counterfeit Drugs); 0 (Drugs, Chinese Herbal); 0 (Fluorenes); 0 (Tablets); 0 (Vitamins); 0 (ledipasvir, sofosbuvir drug combination); 0 (sho-seiryu-to); 013TE6E4WV (ledipasvir); 6FO62043WK (Glycyrrhizic Acid); E2OU15WN0N (Uridine Monophosphate); GN83C131XS (Ephedrine); WJ6CA3ZU8B (Sofosbuvir)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170721
[St] Status:MEDLINE
[do] DOI:10.1248/yakushi.17-00136


  4 / 1395 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28573236
[Au] Autor:Alam P; Foudah AI; Zaatout HH; T KY; Abdel-Kader MS
[Ad] Endereço:Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, P.O. Box 173, Al-Kharj 11942, Saudi Arabia.
[Ti] Título:QUANTIFICATION OF GLYCYRRHIZIN BIOMARKER IN GLYCYRRHIZA GLABRA RHIZOME AND BABY HERBAL FORMULATIONS BY VALIDATED RP-HPTLC METHODS.
[So] Source:Afr J Tradit Complement Altern Med;14(2):198-205, 2017.
[Is] ISSN:2505-0044
[Cp] País de publicação:Nigeria
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: A simple and sensitive thin-layer chromatographic method has been established for quantification of glycyrrhizin in rhizome and baby herbal formulations by validated Reverse Phase HPTLC method. MATERIALS AND METHODS: RP-HPTLC Method was carried out using glass coated with RP-18 silica gel 60 F254S HPTLC plates using methanol-water (7: 3 v/v) as mobile phase. RESULTS: The developed plate was scanned and quantified densitometrically at 256 nm. Glycyrrhizin peaks from rhizome and baby herbal formulations were identified by comparing their single spot at R = 0.63 ± 0.01. Linear regression analysis revealed a good linear relationship between peak area and amount of glycyrrhizin in the range of 2000-7000 ng/band. CONCLUSION: The method was validated, in accordance with ICH guidelines for precision, accuracy, and robustness. The proposed method will be useful to enumerate the therapeutic dose of glycyrrhizin in herbal formulations as well as in bulk drug.
[Mh] Termos MeSH primário: Cromatografia em Camada Delgada/métodos
Glycyrrhiza/química
Ácido Glicirrízico/análise
Extratos Vegetais/química
[Mh] Termos MeSH secundário: Química Farmacêutica
Seres Humanos
Lactente
Reprodutibilidade dos Testes
Rizoma/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Plant Extracts); 6FO62043WK (Glycyrrhizic Acid)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170816
[Lr] Data última revisão:
170816
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170603
[St] Status:MEDLINE
[do] DOI:10.21010/ajtcam.v14i2.21


  5 / 1395 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28549656
[Au] Autor:Wang H; Fang ZZ; Meng R; Cao YF; Tanaka N; Krausz KW; Gonzalez FJ
[Ad] Endereço:School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, PR China; Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
[Ti] Título:Glycyrrhizin and glycyrrhetinic acid inhibits alpha-naphthyl isothiocyanate-induced liver injury and bile acid cycle disruption.
[So] Source:Toxicology;386:133-142, 2017 Jul 01.
[Is] ISSN:1879-3185
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Alpha-naphthyl isothiocyanate (ANIT) is a common hepatotoxicant experimentally used to reproduce the pathologies of drug-induced liver injury in humans, but the mechanism of its toxicity remains unclear. To determine the metabolic alterations following ANIT exposure, metabolomic analyses was performed by use of liquid chromatography-mass spectrometry. Partial least squares discriminant analysis (PLS-DA) of liver, serum, bile, ileum, and cecum of vehicle- and ANIT-treated mice revealed significant alterations of individual bile acids, including increased tauroursodeoxycholic acid, taurohydrodeoxycholic acid, taurochenodeoxycholic acid, and taurodeoxycholic acid, and decreased ω-, ß- and tauro-α/ß- murideoxycholic acid, cholic acid, and taurocholic acid in the ANIT-treated groups. In accordance with these changes, ANIT treatment altered the expression of mRNAs encoded by genes responsible for the metabolism and transport of bile acids and cholesterol. Pre-treatment of glycyrrhizin (GL) and glycyrrhetinic acid (GA) prevented ANIT-induced liver damage and reversed the alteration of bile acid metabolites and Cyp7a1, Npc1l1, Mttp, and Acat2 mRNAs encoding bile acid transport and metabolism proteins. These results suggested that GL/GA could prevent drug-induced liver injury and ensuing disruption of bile acid metabolism in humans.
[Mh] Termos MeSH primário: 1-Naftilisotiocianato/toxicidade
Ácidos e Sais Biliares/metabolismo
Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle
Ácido Glicirretínico/farmacologia
Ácido Glicirrízico/farmacologia
[Mh] Termos MeSH secundário: Animais
Cromatografia Líquida
Regulação da Expressão Gênica/efeitos dos fármacos
Ácido Glicirretínico/administração & dosagem
Ácido Glicirrízico/administração & dosagem
Análise dos Mínimos Quadrados
Fígado/efeitos dos fármacos
Fígado/patologia
Masculino
Espectrometria de Massas
Metabolômica
Camundongos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bile Acids and Salts); 551-06-4 (1-Naphthylisothiocyanate); 6FO62043WK (Glycyrrhizic Acid); P540XA09DR (Glycyrrhetinic Acid)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170913
[Lr] Data última revisão:
170913
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170528
[St] Status:MEDLINE


  6 / 1395 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28542588
[Au] Autor:Liu L; Jiang Y; Steinle JJ
[Ad] Endereço:Department of Anatomy and Cell Biology, Wayne State University School of Medicine, Detroit, Michigan, United States of America.
[Ti] Título:Inhibition of HMGB1 protects the retina from ischemia-reperfusion, as well as reduces insulin resistance proteins.
[So] Source:PLoS One;12(5):e0178236, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The role of inflammation in diabetic retinal amage is well accepted. While a number of cytokines and inflammatory mediators are responsible for these changes, upstream regulators are less well studied. Additionally, the role for these upstream mediators in retinal health is unclear. In this study, we hypothesized that inhibition of high mobility group box 1 (HMGB1) could restore normal insulin signaling in retinal endothelial cells (REC) grown in high glucose, as well as protect the retina against ischemia/reperfusion (I/R)-induced retinal damage. REC were grown in normal (5mM) or high glucose (25mM) and treated with Box A or glycyrrhizin, two different HMGB1 inhibitors. Western blotting was done for HMGB1, toll-like receptor 4 (TLR4), insulin receptor, insulin receptor substrate-1 (IRS-1), and Akt. ELISA analyses were done for tumor necrosis factor alpha (TNFα) and cleaved caspase 3. In addition, C57/B6 mice were treated with glycyrrhizin, both before and after ocular I/R. Two days following I/R, retinal sections were processed for neuronal changes, while vascular damage was measured at 10 days post-I/R. Results demonstrate that both Box A and glycyrrhizin reduced HMGB1, TLR4, and TNFα levels in REC grown in high glucose. This led to reduced cleavage of caspase 3 and IRS-1Ser307 phosphorylation, and increased insulin receptor and Akt phosphorylation. Glycyrrhizin treatment significantly reduced loss of retinal thickness and degenerate capillary numbers in mice exposed to I/R. Taken together, these results suggest that inhibition of HMGB1 can reduce retinal insulin resistance, as well as protect the retina against I/R-induced damage.
[Mh] Termos MeSH primário: Proteína HMGB1/antagonistas & inibidores
Fármacos Neuroprotetores/farmacologia
Traumatismo por Reperfusão/prevenção & controle
Retina/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Células Cultivadas
Modelos Animais de Doenças
Proteínas de Drosophila/farmacologia
Avaliação Pré-Clínica de Medicamentos
Fatores de Transcrição GATA/farmacologia
Glucose/toxicidade
Ácido Glicirrízico/farmacologia
Proteína HMGB1/metabolismo
Seres Humanos
Resistência à Insulina/fisiologia
Masculino
Camundongos Endogâmicos C57BL
Neuroproteção/efeitos dos fármacos
Neuroproteção/fisiologia
Proteínas Proto-Oncogênicas c-akt/metabolismo
Traumatismo por Reperfusão/metabolismo
Traumatismo por Reperfusão/patologia
Retina/metabolismo
Retina/patologia
Doenças Retinianas/tratamento farmacológico
Doenças Retinianas/metabolismo
Doenças Retinianas/patologia
Fator de Necrose Tumoral alfa/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drosophila Proteins); 0 (GATA Transcription Factors); 0 (HMGB1 Protein); 0 (HMGB1 protein, human); 0 (HMGB1 protein, mouse); 0 (Neuroprotective Agents); 0 (Tumor Necrosis Factor-alpha); 0 (serpent protein, Drosophila); 6FO62043WK (Glycyrrhizic Acid); EC 2.7.11.1 (Proto-Oncogene Proteins c-akt); IY9XDZ35W2 (Glucose)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170526
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0178236


  7 / 1395 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28506338
[Au] Autor:Li YW; Hu YH; Zhu TT; Chu AZ; Zhu CL
[Ad] Endereço:Department of Pediatrics, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. zhuchuanlong@jsph.org.cn.
[Ti] Título:[Clinical efficacy of compound glycyrrhizin tablets in the treatment of children with nonalcoholic fatty liver disease].
[So] Source:Zhongguo Dang Dai Er Ke Za Zhi;19(5):505-509, 2017 May.
[Is] ISSN:1008-8830
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:Department of Pediatrics, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. zhuchuanlong@jsph.org.cn.
[Mh] Termos MeSH primário: Ácido Glicirrízico/uso terapêutico
Hepatopatia Gordurosa não Alcoólica/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Criança
Feminino
Seres Humanos
Masculino
Comprimidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Tablets); 6FO62043WK (Glycyrrhizic Acid)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170831
[Lr] Data última revisão:
170831
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170517
[St] Status:MEDLINE


  8 / 1395 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28335563
[Au] Autor:Jiang B; Qu H; Kong H; Zhang Y; Liu S; Cheng J; Yan X; Zhao Y
[Ad] Endereço:School of Basic Medical Sciences, Beijing University of Chinese Medicine, 11 Beisanhuandong Road, Chaoyang District, Beijing 100029, China. 20130941016@bucm.edu.cn.
[Ti] Título:The Effects of Sweet Foods on the Pharmacokinetics of Glycyrrhizic Acid by icELISA.
[So] Source:Molecules;22(3), 2017 Mar 21.
[Is] ISSN:1420-3049
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:The effect of sweet foods, such as honey, was investigated from the perspective of pharmacokinetics on the absorption of glycyrrhizic acid (GA). Due to the unique properties of indirect competitive enzyme-linked immunosorbent assay (icELISA), namely, its: specificity, sensitivity, repeatability, simple pretreatment of samples, fast and simple operation, and because it is economic and non-polluting, it has received increased attention. In this study, we used the advantages of this method to see how honey affected the pharmacokinetics of GA. The effects of honey on the pharmacokinetics of GA by ELISA were investigated for the first time. The results indicate that honey can postpone the peak concentration of GA in mouse blood, and this effect correlates well with fructose. As a representative of sweet foods, the result provides the valuable information that honey, or fructose, may act as sustained-releasing drugs in clinical scenarios; and that sweet foods may have some influences on drugs when taken together.
[Mh] Termos MeSH primário: Ensaio de Imunoadsorção Enzimática/métodos
Frutose/análise
Ácido Glicirrízico/farmacocinética
Mel/análise
[Mh] Termos MeSH secundário: Animais
Análise Química do Sangue
Camundongos
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
30237-26-4 (Fructose); 6FO62043WK (Glycyrrhizic Acid)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170517
[Lr] Data última revisão:
170517
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170325
[St] Status:MEDLINE


  9 / 1395 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28315871
[Au] Autor:Deng QP; Wang MJ; Zeng X; Chen GG; Huang RY
[Ad] Endereço:The Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China.
[Ti] Título:Effects of Glycyrrhizin in a Mouse Model of Lung Adenocarcinoma.
[So] Source:Cell Physiol Biochem;41(4):1383-1392, 2017.
[Is] ISSN:1421-9778
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Currently, there is a global attempt to identify potential anti-cancer agents with low toxicity. Previous studies have found that glycyrrhizin exerts anti-cancer action with low toxicity through suppressing thromboxane A2 (TxA2) in lung cancer cell lines. However, these effects have not yet been determined in animal models of lung cancer. METHODS: Human lung adenocarcinoma xenografts were established in nude mice by the introduction of A549 cells with stable transfection of the TxA2 receptor (TPα). The animal model was confirmed by the hematoxylin and eosin (H&E) method. Tumor-bearing mice were then administered graded concentrations of glycyrrhizin, cisplatin or both. After the treatments, body weights of all animals were recorded, and immunohistochemistry staining of lung tissues and serum biochemistry detection of aspartate amino transferase (AST), alanine amino transferase (ALT), urea and creatinine were carried out. RESULTS: Treatment with glycyrrhizin alone or the combination of cisplatin and glycyrrhizin profoundly reduced expression of thromboxane synthase (TxAS) as well as proliferating cell nuclear antigen (PCNA), recovered the body weight, and rescued damage of liver and kidney in tumor-bearing mice. Although it inhibited PCNA expression, cisplatin could not significantly suppress TxAS expression. Because of a positive feedback loop between TPα and TxAS, the effects of glycyrrhizin are possibly attributable to the suppression of the TxA2 pathway. CONCLUSIONS: This study provides in vivo evidence to support glycyrrhizin as a potential candidate for developing new regimens to overcome tumor progression and the resistance and toxicity of cisplatin.
[Mh] Termos MeSH primário: Adenocarcinoma/tratamento farmacológico
Ácido Glicirrízico/farmacologia
Neoplasias Pulmonares/tratamento farmacológico
Neoplasias Pulmonares/metabolismo
Neoplasias Experimentais/tratamento farmacológico
Neoplasias Experimentais/metabolismo
[Mh] Termos MeSH secundário: Células A549
Adenocarcinoma/metabolismo
Adenocarcinoma/patologia
Animais
Cisplatino/farmacologia
Feminino
Seres Humanos
Neoplasias Pulmonares/patologia
Camundongos
Camundongos Nus
Neoplasias Experimentais/patologia
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
6FO62043WK (Glycyrrhizic Acid); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170621
[Lr] Data última revisão:
170621
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170320
[St] Status:MEDLINE
[do] DOI:10.1159/000467897


  10 / 1395 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:28314257
[Au] Autor:Hostetler BJ; Uchakina ON; Ban H; McKallip RJ
[Ad] Endereço:Division of Basic Medical Sciences, Mercer University School of Medicine, Macon, GA, U.S.A.
[Ti] Título:Treatment of Hematological Malignancies with Glycyrrhizic Acid.
[So] Source:Anticancer Res;37(3):997-1004, 2017 03.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:The current study examined the effectiveness of glycyrrhizic acid (GA) in reducing cell viability and inducing apoptosis in human chronic myeloid leukemia (CML) in vitro and a mouse lymphoma in vivo. Additionally, we assessed GA as a candidate for combinational therapy in CML along with the current frontline treatment, imatinib (IM). Treatment of K562 CML cells with GA alone resulted in significant induction of apoptosis and loss of cell viability. GA was well tolerated by peripheral blood mononuclear cells (PBMCs) up to 2 mM doses which were subsequently used in combination with IM. Co-treatment of CML with GA and IM greatly enhanced the levels of apoptosis in human CML. The effectiveness of GA was not limited to in vitro studies as treatment of EL-4 lymphoma-bearing mice with GA (50 or 500 mg/kg/day) led to significant dose-related decrease in tumor burden that correlated with a significant increase in the level of apoptotic tumors in vivo. The broad activity of GA against different tumor cell types, its tolerance by PBMCs and synergistic effects when combined with IM suggests that GA may be a viable candidate for combinational treatment strategies in CML and other hematological malignancies.
[Mh] Termos MeSH primário: Ácido Glicirrízico/uso terapêutico
Neoplasias Hematológicas/tratamento farmacológico
Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico
Linfoma/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/uso terapêutico
Apoptose
Linhagem Celular Tumoral
Sobrevivência Celular
Seres Humanos
Mesilato de Imatinib/uso terapêutico
Células K562
Leucócitos Mononucleares/citologia
Camundongos
Transplante de Neoplasias
Espécies Reativas de Oxigênio/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Reactive Oxygen Species); 6FO62043WK (Glycyrrhizic Acid); 8A1O1M485B (Imatinib Mesylate)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170411
[Lr] Data última revisão:
170411
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170319
[St] Status:MEDLINE



página 1 de 140 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde